can we target kras effectively in advanced nsclc?
Published 11 years ago • 225 plays • Length 4:04Download video MP4
Download video MP3
Similar videos
-
2:45
kras mutations in advanced nsclc - 2022 program: targeted therapies forum - english
-
4:04
challenges of targeted kras treatment & current treatments - targeted therapies in lung cancer 2023
-
9:26
gracecast - lcvl - which patients with advanced nsclc are good candidates for first line immunothera
-
4:57
could braf be a new target in nsclc?
-
10:03
kras nsclc: details and diagnosis - targeted therapies in lung cancer 2023
-
14:53
why is immunotherapy more effective in some cancers than others? - part 2
-
4:56
immunotherapy for previously treated advanced non-small cell lung cancer
-
12:50
avastin-containing regimen for first line and maintenance therapy in advanced nsclc
-
4:37
gracecast - lcvl - what are the leading first line treatment options for advanced nsclc harboring an
-
12:25
adagrasib for previously treated kras g12c nsclc - asco lung review 2022
-
33:47
gracecast-049_lung-cancer_weiss on egfr therapy for early stage nsclc
-
3:02
the future of ret nsclc treatment - targeted therapies in lung cancer 2023
-
3:15
q&a: kras nsclc, non-smoker - benefit from immunotherapy? - targeted therapies in lung cancer 2023
-
2:40
krystal 7 study: adagrasib /- pembrolizumab for kras g12c nsclc -targeted therapies in lung cancer
-
3:27
emerging molecular targets for advanced non small cell lung cancer nsclc
-
3:56
kras g12c inhibitors versus chemotherapy in second line - targeted therapies in lung cancer 2023
-
3:56
preferential timing for molecular testing in nsclc
-
4:17
how should we integrate new immunotherapies into treatment strategies for lung cancer?
-
4:05
basic principles of managing locally advanced nsclc